Introduction {#Sec1}
============

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease (COVID-19), has rapidly spread worldwide. As of 28th May 2020, there have been an estimated 269,127 confirmed cases reported in the UK with over 37,837 deaths \[[@CR1]\]. London and the West Midlands have been the epicenters in the UK.

To date, there have been very few cases of children being seriously affected by SARS-Cov-2 respiratory illness \[[@CR2], [@CR3]\]. However, particularly in Europe and parts of North America, children have been presenting with a systemic inflammatory response, sharing features with other paediatric inflammatory conditions including Kawasaki disease (KD), toxic shock syndrome (TSS), bacterial sepsis and macrophage activation syndrome (MAS). Initial reports suggest many have myocardial dysfunction \[[@CR4]\] and coronary artery involvement \[[@CR5]\] in addition to gastrointestinal and systemic symptoms \[[@CR6]--[@CR8]\].

This experience has been mirrored in the UK, prompting an alert and guideline from the Royal College of Paediatrics and Child Health (RCPCH) \[[@CR9]\] for "Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS)" with a case definition (Table [1](#Tab1){ref-type="table"}). The Centers for Disease Control and Prevention (CDC) have also issued an alert on this condition, under the label "Multisystem Inflammatory Syndrome in Children (MIS-C) \[[@CR10]\]. In response, we created a paediatric multi-disciplinary team (MDT) including cardiologists, general paediatricians, rheumatologists, infectious disease specialists, immunologists, paediatric intensivists, retrieval team, and pharmacists. We also developed a West Midlands regional management guideline to serve a population of over 1 million children \[[@CR11]\].Table 1RCPCH case definition for PIMS-TS, including Clinical features and abnormalities seen on recommended investigations \[[@CR5]\]*RCPCH case definition*1. A child presenting with persistent fever, inflammation (neutrophilia, elevated CRP and lymphopenia) and evidence of single or multi-organ dysfunction (shock, cardiac, respiratory, renal, gastrointestinal or neurological disorder) with additional features (see below).This may include children fulfilling full or partial criteria for Kawasaki disease2. Exclusion of any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes, infections associated with myocarditis such as enterovirus (waiting for results of these investigations should not delay seeking expert advice).3. SARS-CoV-2 PCR testing may be positive or negative*Imaging and ECG*Echocardiogram & ECG---myocarditis,Valvulitis, pericardial effusionCoronary artery dilatationCXR---patchy symmetrical infiltrates, pleural effusionAbdo USS---colitis, ileitisLymphadenopathy, ascitesHepatosplenomegalyCT chest---patchy symmetrical infiltrates, pleural effusion, mayDemonstrate coronary arteryAbnormalities if with contrast*ClinicalAll*Persistent fever \> 38.5 °C*Most*Oxygen requirementHypotension*Some*Abdominal painConfusionConjunctivitisCoughDiarrhoeaHeadacheLymphadenopathyMucus membrane changesNeck swellingRashRespiratory symptomsSore throatSwollen hands and feetSyncopeVomiting*LaboratoryAll*Abnormal FibrinogenAbsence of potential causativeorganisms (other than SARS-CoV-2)High CRPHigh D-DimersHigh ferritinHypoalbuminemiaLymphopeniaNeutrophilia in most---normalneutrophils in some*Some*Acute kidney injuryAnaemiaCoagulopathyHigh IL-10\*High IL-6\*NeutrophiliaProteinuriaRaised CKRaised LDHRaised triglyceridesRaised troponinThrombocytopeniaTransaminitis*RCPCH* indicates Royal College of Paediatrics and Child Health, *PIMS-TS* paediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2, *SARS-CoV-2* severe acute respiratory syndrome coronavirus 2, *CRP* C-reactive protein, *PCR* polymerase chain reaction, *ECG* electrocardiogram, *CXR* chest x-ray, *USS* ultrasound scan, *CT* computerized tomography, *IL* interleukin, *CK* creatinine kinase, *LDH* lactate dehydrogenase\*These assays are not widely available. CRP can be used as a surrogate marker for IL-6

This article describes the cardiac manifestations, management and early outcomes for children admitted to Birmingham Children's Hospital (BCH) with PIMS-TS.

Methods {#Sec2}
=======

We performed a single-center retrospective study of all patients referred for cardiovascular evaluation as confirmed PIMS-TS between 10th April 2020 and 9th May 2020. Children presenting with persistent fever, features of clinical and biochemical inflammation, single or multi-organ dysfunction, and/or fulfilling the full or partial criteria for KD were reviewed for possible PIMS-TS at the daily MDT meeting. Diagnostic criteria for PIMS-TS were based on the RCPCH case definition \[[@CR13]\] (Table [1](#Tab1){ref-type="table"}).

The study was classified and registered as service evaluation following assessment using the UK NHS research governance assessment tool (<https://www.hra-decisiontools.org.uk/research/>). The study was then reviewed by the Research Governance department at our institution (Birmingham Women's and Children's NHS Foundation Trust) and deemed to not require ethical approval (R&D Director's letter of approval available). All patients and/or their parents/legal guardians provided signed informed consent to inclusion of de-identified data in this report.

Description of ethnicity was in accordance with the UK Government classification \[[@CR12]\]. Investigations were based on an amalgamation of RCPCH guidelines and MDT recommendations (Table [2](#Tab2){ref-type="table"}). All patients had nose and throat swab viral PCR (polymerase chain reaction) for SARS-CoV-2. Patients had immunological testing for Immunoglobulin M (IgM), Immunoglobulin A (IgA) and Immunoglobulin G (IgG) to viral spike glycoprotein using an Enzyme-Linked Immunosorbent Assay (ELISA) test. Blood, urine and cerebrospinal fluid cultures, viral serology, and PCR panel of respiratory pathogens were used to detect/exclude other causes. Chest radiographs, abdominal ultrasound and other investigations were performed as clinically indicated. Patients had daily 12 lead Electrocardiogram (ECG) and echocardiogram initially, then as required following clinical stability.Table 2Investigations as part of PIMS-TS screenBlood testsMicrobiology FBC and Film Blood culture U + E Urine and stool culture LFT Throat swab culture CRP NPA or throat swab for respiratory panel ESR Mycoplasma titres Glucose Pneumococcal, Meningococcal, Group A strep, Staph aureus Blood PCR Blood gas with lactate Coagulation + Fibrinogen D-Dimer Anti-Streptolysin O Titre LDH EBV, CMV, Adenovirus, Parvovirus, Enterovirus PCR on Blood Triglycerides Ferritin HIV Troponin I Blood for enterotoxin/staph toxins Pro-BNP Stool for virology CK Vitamin D Amylase Save EDTA and serum for PCR and serological studies (pre IVIG)Cardiac investigationsSARS-CoV-2 Investigations ECG SARS-CoV-2 Respiratory PCR Echocardiogram Consider PCR on stool and blood SARS-CoV-2 serology*PIMS-TS* indicates paediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2, *SARS-CoV-2* severe acute respiratory syndrome coronavirus 2, *FBC* full blood count, *U* + *E* urea and electrolytes, *LFT* liver function test, *CRP* C-reactive protein, *ESR* erythrocyte sedimentation rate, *LDH* lactate dehydrogenase, *BNP* B type natriuretic peptide, *CK* creatinine kinase, *EDTA* ethylenediaminetetraacetic acid, *PCR* polymerase chain reaction, *IVIG* intravenous immunoglobulin, *ECG* electrocardiogram, *NPA* nasopharyngeal aspirate, *EBV* Epstein-Barr virus, *CMV* cytomegalovirus, *HIV* human immunodeficiency virus

ECGs were reported contemporaneously and re-analyzed by a single author (ON). All echocardiograms were performed on Vivid S70 GE system, and analyzed using EchoPac software. Using American Society of Echocardiography guidelines \[[@CR16]\] data were analyzed immediately by the operator, and re-analyzed independently by one author (TR). Any discrepancies between the initial reports and re-analysis of ECGs and echocardiograms were reviewed by the senior author (AC).

Global left ventricular (LV) systolic function was assessed with linear and 2D methods \[[@CR16]\].Fractional shortening (FS) was based on M-mode (Motion-Mode) and categorized as either normal (25--43%), or mild (20--24%), moderate (15--19%) or severe reduction (≤ 14%) \[[@CR16]\].Left ventricular ejection fraction (LVEF) was based on modified Simpson's method and categorized as either normal (≥ 55%), or mild (45--54%), moderate (30--44%) or severe impairment (\< 30%) \[[@CR16]\].Where mitral regurgitation was present, change of pressure over time (dP/dt) was used, and categorized into either normal (\> 1200 mmHg/s), or mild (901--1200 mmHg/s), moderate (600--900 mmHg/s) or severe impairment (\< 600 mmHg/s).

We accepted LVEF and a subjective assessment of the global LV function as more reliable than FS in case of discrepancy, keeping with institutional practice of using FS as a screening tool only for systolic function assessment.

Mitral annular plane systolic excursion (MAPSE), tricuspid annular plane systolic excursion (TAPSE) and z-scores were used to assess ventricular longitudinal function \[[@CR17], [@CR18]\]. LV diastolic function was assessed using mitral inflow ratio (E/A), and mitral annular tissue doppler (E/E′) \[[@CR21]\]. Coronary artery measurements were from inner edge to inner edge, and z-scores calculated \[[@CR19]\]. Aneurysms were described as saccular or fusiform and classified as small (\< 5 mm), moderate (5--8 mm) or large (\> 8 mm) \[[@CR14]\]. Dilated coronary arteries without segmental aneurysm were defined as ectatic \[[@CR14]\].

CT angiogram of abdomen, thorax and head & neck was planned for the second week of illness in those patients (1) with coronary aneurysms, (2) who did not respond to first line therapy, or (3) with suboptimal clinical/biochemical resolution following first line therapy. Any patients with abnormal coronary arteries are planned for coronary CT during follow-up. Cardiac MRI has been reserved for surveillance protocol.

Treatment {#Sec3}
---------

Patients had immunomodulatory treatment after a case-by-case MDT discussion, and supportive treatment as per hospital standards of care. If indicated following MDT discussion, children were given intravenous immunoglobulins (IVIG) at a dose of 2 g/kg and high-dose aspirin at a dose of 12.5 mg/kg four times a day (QID). In response to this first line therapy, patients with persistent fever and/or worsening inflammatory markers after 36 h received a second dose of IVIG, and/or a three-day course of intravenous (IV) methylprednisolone, followed by a weaning course of oral prednisolone. Infliximab was reserved for those who did not respond to this treatment.

Systemic hypotension was treated with intravenous fluid boluses as first line therapy and with norepinephrine and vasopressin as second line. Intravenous hydrocortisone was used for refractory hypotension. Epinephrine was used for LV dysfunction (based on FS & LVEF). Thromboprophylaxis with antiplatelet therapy and anti-coagulation was based on standard criteria \[[@CR15]\] and hospital protocols.

Data analysis was performed using Microsoft Excel (Microsoft Corporation, Redmond, USA). Continuous data are presented as median (Inter-quartile range (IQR)) and categorical data as numbers and percentages. Where serial data were available, median (IQR) of the highest or lowest result per patient is presented as median peak or nadir result.

Results {#Sec4}
=======

Demographics and Clinical Presentation {#Sec5}
--------------------------------------

During this 1-month study period, 15 patients met the case definition for PIMS-TS (Table [3](#Tab3){ref-type="table"}). The median age was of 8.8 years (IQR 6.4--11.2 years). Notably 14 (93%) were over 5 years of age. Eleven out of 15 (73%) were male. All patients were from African/Afro-Caribbean, South Asian, Mixed or other minority ethnic groups (Table [3](#Tab3){ref-type="table"}).Table 3Overview of patient cohortTotal patients (n = 15) Median age (IQR) years8.8 (6.4--11.2) Gender (male: female)2.75:1 Median weight (IQR) kg34.7 (24.2--40.2) Median height (IQR) cm137.6 (128.9--146.5)Ethnicity in number (percentage) African/Afro-Caribbean6 (40%) South Asian6 (40%) Mixed2 (13%) Other1 (7%)PICU support in number (percentage) Respiratory support\*8 (53%) Inotrope or vasopressor^a^10 (67%)Blood results median (IQR range): Ferritin peak (ng/mL)Normal 14--79558 (364--1325) CRP peak (mg/L)Normal \< 10154 (129--231) ESR peak (mm/hr)Normal 0--975 (45--90) D-dimer peak (µg/mL)Normal \< 0.302.06 (1.16--2.61) Troponin I peak (ng/L)Normal \< 35 ng/L396 (100--1280) Pro-BNP peak (pg/mL)Normal \< 40024,470 (17,212--26,655) CK peak (U/L)Normal 75--235385 (117--1615)*PICU* indicates paediatric intensive care unit, *CRP* C-reactive protein, *ESR* erythrocyte sedimentation rate, *BNP* B- type natriuretic peptide, *CK* creatinine kinase\*Included invasive mechanical ventilation or humidified high-flow nasal prong oxygen^a^Included epinephrine, norepinephrine or vasopressin

All 15 patients presented with pyrexia (median duration of 5 days). Thirteen (87%) had gastrointestinal symptoms and 8 (53%) had features of Kawasaki disease not fulfilling diagnostic criteria. Generalized myalgia and lethargy were also reported in 4 patients each (27%).

Two patients described typical COVID-19 symptoms in the previous two months, both of whom had positive SARS-CoV-2 PCR. Another 3 patients had family members with COVID-19 symptoms in the preceding 2 months.

Investigations {#Sec6}
--------------

Blood results (Table [3](#Tab3){ref-type="table"}) showed raised inflammatory markers (C-reactive protein, ESR, ferritin) during the early part of the disease in keeping with published studies \[[@CR5], [@CR20]\]. Median peak C-reactive protein (CRP) was 154 (IQR 42--265)mg/L, median ESR was 75 (IQR 45--90)mm/h, and median peak ferritin 558 (IQR 31--2891)ng/mL. Cardiac markers were elevated in all patients with median peak Troponin I 396 (IQR 100--1280)ng/L, Creatine Kinase (CK) median peak 385 (IQR 117-1615)U/L and pro-B-type Natriuretic Peptide (pro-BNP) median peak 24,470 (IQR 17,212--26,655)pg/mL. The median peak for all three cardiac markers was on day 2 of hospital admission with gradual improvement thereafter.

Two patients had positive SARS-CoV-2 PCR, one at the time of admission and one four weeks previously. SARS-CoV-2 serology was available for 12 of 15 patients, all of whom were positive for the combined IgG, IgA and IgM ELISA.

Fourteen patients had chest radiographs; 7 were normal, 7 had abnormalities including pleural effusions (5), consolidation (3), cardiomegaly (2). Six patients had abdominal ultrasound due to persistent gastrointestinal symptoms, showing no abnormalities.

During their admission, two patients had non-coronary CT Angiograms and one had a MRI whole body, due to persisting inflammation despite treatment, all of which showed no evidence of vasculitis.

Cardiac Investigations {#Sec7}
----------------------

Nine patients (60%) had abnormalities on ECG (Table [4](#Tab4){ref-type="table"}). Six of these had normalization of their ECG prior to discharge at median 5 days.Table 4ECG changes in individual patientsAt admissionAt dischargeRhythmPR IntervalQRS IntervalT wavesST1NNNANA2NNNANN3NNNANN4NNNANN5NNNANN6NNNANN7NNNNNN8NNNNNN9NANNNA10NNNNNN11NANANA12NNNNNN13NNNNNN14NNNNNN15NNNANN*ECG* indicates electrocardiogram, *N* normal, *A* abnormal

### Coronary Arteries {#Sec8}

Fourteen patients (93%) had coronary artery abnormalities noted on echocardiography, which we have described as prominent, dilated or aneurysmal (Table [5](#Tab5){ref-type="table"}). Of these:1 had moderate fusiform aneurysm of right coronary artery (RCA) and small fusiform aneurysm of left anterior descending artery (LAD)6 had ectatic dilated coronaries with increased z-scores of either left main coronary artery (2 patients) or left anterior descending artery (4 patients).7 had prominent coronary arteries on echocardiogram but normal measurements.Table 5Coronary artery changes seen in individual patientsAt admissionMost abnormalAt discharge1NNN2DDN3PPN4PPP5PPN6DDD7AAA8DDD9DDN10PPP11PPP12PPP13NPN14DDD15DDN*A* indicates aneurysmal, *D* dilated, *P* prominent, *N* normal

Of the 14 patients with coronary changes, 13 (93%) had changes at presentation whilst 1 (7%) developed abnormal appearance on day 5 of admission. In 6 (43%) the coronary appearance normalized at a median 3 days, whilst the other 8 continued to have abnormal appearances at discharge.

### Atrioventricular Valve Regurgitation (AVVR) (Table [6](#Tab6){ref-type="table"}) {#Sec9}

###### 

Degree of atrioventricular valve regurgitation in individual patients

       At worst   At discharge       
  ---- ---------- -------------- --- ---
  1    N          M              N   N
  2    M          M              N   N
  3    N          N              N   T
  4    M          M              N   N
  5    T          T              N   T
  6    M          M              M   T
  7    N          T              N   T
  8    T          T              T   T
  9    N          M              N   M
  10   M          T              M   T
  11   M          M              N   M
  12   M          T              T   T
  13   M          Mo             T   M
  14   N          M              N   N
  15   Mo         M              N   N

*N* indicates no regurgitation, *T* trivial, *M* mild, *Mo* moderate

Thirteen patients had AVVR during admission, of which 10 had mitral regurgitation. There was serial improvement in 7 of these 10 patients, at median 2 days. Nine had non-physiological tricuspid regurgitation (mild-moderate), 5 of which improved at median 1 day after treatment. At discharge 7 patients had residual non-physiological AVVR. No patients had valve stenosis.

### Ventricular Function (Tables [7](#Tab7){ref-type="table"} and [8](#Tab8){ref-type="table"}) {#Sec10}

###### 

Details of echocardiogram results of children with PIMS-TS (*n* = 15)

                     Admission result (median)   Discharge (median)   Patients with impaired function   
  ------------------ --------------------------- -------------------- --------------------------------- ---
  LV FS\* (%)        29                          35                   18                                3
  LVEF^a^ (%)        51                          58                   43.5                              4
  MR dP/dt(mmHg/s)   1140                        1584                 956                               4
  MAPSE (z-score)    − 2.8                       + 0.6                − 3.6                             5
  TAPSE (z-score)    − 2.4                       + 2.7                − 3.7                             3

*PIMS-TS* indicates paediatric inflammatory multisystem syndrome-temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), *LV* left ventricle, *FS* fractional shortening, *EF* ejection fraction, *MR* mitral regurgitation, *dP/dt* change of pressure over time, *MAPSE* mitral annular plane systolic excursion, *TAPSE* tricuspid annular plane systolic excursion

\*FS was assessed using standard M-mode in parasternal views

^a^EF was estimated using modified Simpson's method on 2D

###### 

Individual patient echocardiogram results when most impaired during admission and at discharge

       Most impaired   FS (%)   LVEF (%)   dP/dt (mmHg/s)   MAPSE z-score   At discharge   FS (%)   LVEF (%)   dP/dt (mmHg)   MAPSE z-score
  ---- --------------- -------- ---------- ---------------- --------------- -------------- -------- ---------- -------------- ---------------
  1    S               16       28                          − 3.1           M              30       53                        − 1.6
  2    M               20       42         863              − 5.3           N              35       66         1237           − 3.4
  3    M               17       43                          − 4.1           N              31       57                        1.5
  4    Mo              20       32         844              − 3.6           N              43       57         1586           − 1.2
  5    M               23       45         1246             − 4.5           N              30       55                        − 0.8
  6    M               28       50         1584             − 3.3           N              35       64         1584           − 1.9
  7    M               32       51                          2.8             N              41       58                        3.6
  8    M               32       50                          2.8             M              35       50                        1.7
  9    N               29       56                          − 3.4           N              42       63                        3
  10   N               34       55         2800                             N              34       55                        
  11   Mo              16       38         1140             − 3.4           N              35       59                        1.3
  12   M               33       53                          − 3.6           N              35       55                        − 0.7
  13   Mo              18       37                          − 3.1           N              30       69                        4.2
  14   N               34       62                          − 4.2           N              34       72                        2.1
  15   M               18       44         1048             − 0.03          N              32       64                        − 0.03

*FS* indicates fractional shortening, *LVEF* left ventricular ejection fraction, *dP/dt* difference of pressure over time, *MAPSE* mitral annular plane systolic excursion, *N* normal, *M* mildly impaired, *Mo* moderately impaired, *S* severely impaired

Fractional Shortening was reduced in 8 patients, of whom 7 had changes on presentation and 1 developed subsequent changes. For those with impaired function, median FS at its nadir was 18% (IQR 17--20%) and all normalized before discharge (median 3 days).

LV ejection fraction was impaired in 12 patients (80%), 9 at presentation and in 3, there was a reduction after admission. For those with impaired function, the median of the lowest LVEF was 44% (IQR 38--50%). One patient had severe impairment on presentation (LVEF 28%) with improvement to mild impairment (LVEF 53%) at discharge. Three had moderate impairment which all normalized by discharge. The remaining 8 patients had mild impairment, of whom 7 had normalization of LVEF at discharge and 1 had an EF of 50%. Overall, normalization of LVEF took median 4 days in these 10 patients.

MAPSE z-score was reduced in 11 patients, of whom 10 had normalization after a median of 5 days.

MR dP/dt was available on admission echocardiograms in 7 patients, in whom 4 had impairment (2 mild, 2 moderate). In the 2 patients with mild impairment, mitral regurgitation resolved after the initial echocardiogram and so repeat assessment of *d*P/*d*t was not possible. For the other 2 patients with moderate impairment, MR was still present and they had normalized *d*P/*d*t at median 4 days.

In the 12 patients with LV dysfunction by ejection fraction, 9 also had reduced MAPSE on z-score, 8 had reduced fractional shortening, and 4 reduced MR *d*P/*d*t. Of these 12 with impaired LVEF, 10 normalized prior to discharge and the remaining 2 had mild impairment (LVEF 50% and 53%) at discharge.

Two patients had evidence of diastolic dysfunction with abnormal E/A and E/E′ ratios.

RV systolic function was assessed using tricuspid annular excursion (TAPSE). Using z-scores of TAPSE, 10 patients had impaired RV function with normalization in all at median 3 days. Subjective assessment of RV size and function did not show any abnormalities at any point.

### Effusions {#Sec11}

Small pericardial effusion was present in 8 patients, half had complete resolution by discharge at median 5 days. The remaining 4 had small pericardial effusion at discharge.

Management {#Sec12}
----------

Ten patients received intravenous immunoglobulin (IVIG), of whom 2 received a second dose. Five patients received IV methylprednisolone followed by weaning course of oral prednisolone. No patients needed Infliximab. None needed therapeutic anti-coagulation. Eleven patients (73%) were discharged on low dose aspirin with 2 requiring high doses initially. All patients were treated with broad-spectrum antibiotics for at least 5 days. Ten (67%) needed intensive care with a median stay of 4 days (IQR 3--5 days). Eight needed respiratory support, of whom half required mechanical ventilation (median 3 days) and others required high-flow nasal cannula support.

### Cardiovascular Support {#Sec13}

Ten patients (67%) needed fluid resuscitation with a median of 58 mL/kg (IQR 35-60 mL/kg) intravenous fluid boluses given. Ten (67%) required inotropes/vasopressors for a median of 3 days (IQR 2--3 days). Norepinephrine was used in 8 with additional support using vasopressin in 3 to treat systemic hypotension. Intravenous hydrocortisone was used for refractory hypotension in 8 patients. Nine required epinephrine to support LV dysfunction. One patient was transferred from an external hospital on milrinone, which was weaned off.

No patients needed extracorporeal life support (ECLS) in our cohort.

Short-Term Outcomes {#Sec14}
-------------------

There were no deaths in our cohort. Median inpatient stay was 12 days (IQR 9--13 days). All 15 patients were discharged home clinically well with normal/improving biochemical and cardiac parameters. All are planned for clinical review one week after discharge in a multi-disciplinary clinic with repeat blood tests, ECG & echocardiogram.

Twelve patients (80%) have had their first clinic review with stable clinical and echocardiogram findings. There were no new coronary changes and no deterioration in cardiac function. Two patients have had outpatient CT coronary angiogram, both of which have mirrored echocardiographic findings with no new abnormalities.

Discussion {#Sec15}
==========

The focus of this descriptive study of PIMS-TS patients from a single cardiac center is on cardiac involvement with short-term outcomes. Although our patients shared some overlapping features with Kawasaki disease, we have identified some distinct features in our cohort suggesting a different pathological process as described below.

The median age of children in our cohort was 8.8 years, with none in the neonatal age group. In our cohort patients were older when compared to acute COVID-19 infection, where severe illness was seen more commonly in younger children \[[@CR2]\]. In addition, the median age of our cohort is above the median age of children affected with Kawasaki disease in UK (\< 5 years) \[[@CR22]\].

All children were from African/Afro-Caribbean, South Asian, Mixed or other minority ethnic groups, which is disproportional to the ethnic demographics of children in the West Midlands (3.3% Black, 10% Asian) \[[@CR23], [@CR24]\]. This mirrors evidence that people from such communities are at increased risk of not only acquiring COVID-19 infection, but also having worse outcomes \[[@CR25], [@CR26]\].

Paediatric Intensive Care (PIC) Support {#Sec16}
---------------------------------------

Ten patients (67%) needed intensive care treatment and monitoring, mainly for their cardiovascular instability, with 8 of these patients also requiring respiratory support. This need for intensive care support is comparable to the other hitherto published studies, with 50% of patients in the Bergamo series \[[@CR20]\] and 70% of the patients in the Paris study (pre-print) \[[@CR26]\] needing intensive care admission.

Cardiac Manifestations {#Sec17}
----------------------

All patients in our cohort had evidence of cardiac involvement based on biochemical, ECG and echocardiogram data (Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, and [8](#Tab8){ref-type="table"}). This is significantly higher compared to the Bergamo series \[[@CR20]\] where 60% had cardiac involvement in the form of echocardiogram abnormalities, and the Paris series (pre-print) \[[@CR26]\] where myocarditis was described in 70% of patients.

### Biochemical Markers {#Sec18}

Cardiac biochemistry markers peaked at median day 2 of admission, with gradual improvement. This preceded improvement in ECG appearances and cardiac function, which showed an improvement by median days 5 and 4, respectively. We could therefore be reassured by biochemical improvement and use this along with ECG/echocardiographic improvement as confirmation of clinical improvement.

### Systemic Hypotension {#Sec19}

This is present in only 5% of KD patients \[[@CR14]\], but common in our cohort (67% needing fluid resuscitation/inotropic/vasopressor support) in keeping with the Bergamo data at 50% \[[@CR20]\].

### AV Valve Regurgitation {#Sec20}

Mitral and/or tricuspid valve regurgitation was present in 13 patients (87%), with significant improvement at median 1--2 days suggesting a transient valvulitis.

### LV Function {#Sec21}

There was global LV dysfunction in 12 patients (80%) by LVEF, with normalization occurring in 10 children by discharge. This is higher than that in the Bergamo cohort with 50% of patients having abnormal LVEF \[[@CR20]\] and is comparable to the Paris cohort (pre-print) with 71% of patients having abnormal LVEF \[[@CR26]\]. In addition, mild LV dysfunction was noted in 4 patients on eyeballing and LVEF (Simpson's method) when the shortening fraction was normal. This highlights the need for specialist and thorough cardiac evaluation of all patients with PIMS-TS.

### Coronary Arteries {#Sec22}

Although only half of our patients with abnormal coronary artery appearances had objective dilation, the remaining half were subjectively reported to be "echo-bright" by at least 2 different observers. Notably, the coronary arteries in the older children were visualized much easier than would be expected on echocardiography. This mirrors the description of the Paris group (pre-print) \[[@CR26]\] with coronary involvement in 45% of cases (no aneurysms, 29% dilated), and of the Evelina (London) group with reports of "echo-bright coronary vessels" \[[@CR5]\]. This may be explained by endothelial inflammation of coronary arteries and warrants careful monitoring over time to identify coronary artery complications.

### Management {#Sec23}

The focus of management was to modulate hyperinflammation. From a cardiovascular perspective, patients mainly needed vasopressor support for hypotension. One patient was started on milrinone at another center prior to transfer and this was weaned off after admission. Our institutional preference is a combination of norepinephrine and vasopressin to support blood pressure. Epinephrine was used to support LV dysfunction. The use of milrinone as an inotrope was avoided in this cohort due to the counterproductive effect of peripheral vasodilation. All patients were discharged on low dose aspirin to reduce the incidence of coronary artery events.

### Follow-Up {#Sec24}

All patients were clinically well at the time of discharge, and 12 have had their first follow-up review with no clinical concerns. Echocardiogram and CT coronary angiograms have confirmed no new findings or deterioration. These reflect the clinical improvement seen prior to discharge with good short-term outcomes.

### Strengths and Limitations {#Sec25}

This study has the limitations of representing a small case series and requires further collaboration at national and international levels. The management described cannot be construed as treatment recommendations. Some other patients in the region, especially with milder illness may have not been referred to our hospital. Only short-term outcomes have been described. Long term follow-up is planned and would be essential to define the late outcomes for this patient cohort. Strengths of the study include detailed granular cardiac data in the small number of patients described and the consistent multi-disciplinary team involvement, which reduced some of the variability in management. Further research is needed to understand the epidemiology, natural history, and immunopathology of PIMS-TS.

Summary {#Sec26}
=======

We have described a detailed cardiac assessment of a cohort of patients with PIMS-TS. All the patients in our cohort had impaired left ventricular function, valve regurgitation and/or coronary artery involvement, with good recovery in most by the time of discharge. There was a high incidence of cardiovascular instability with systemic hypotension. Early management was targeted to reduce inflammation and medium to long-term complications. However, long-term follow-up will be essential and cardiac vigilance is needed in paediatric and potentially adult cohorts, as this condition is understood further.
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